Phase 1/2CompletedAge-related condition

Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells (MSV_allo)

Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells (MSV*) *MSV: Mesenchymal Stromal Cells From Valladolid

Sponsor
Red de Terapia Celular (Industry)
Enrollment
30 enrolled
Conditions
Osteoarthritis, Knee; Arthritis of Knee; Knee Osteoarthritis
Interventions
Allogenic mesenchymal stromal cells injection; Hyaluronic Acid
Ages
adults, older adults
Registry
NCT01586312, EUCTR2011-005321-51

Full record on ClinicalTrials.gov

From the registry

In this study we want to evaluate the clinical use of allogenic mesenchymal stem cells (MSC), obtained from bone marrow of healthy donors, for treatment of knee osteoarthritis. The trial is based in our own previous results with autologous MSC (ongoing NCT01183728 trial). We propose here a multicenter, phase I-II clinical trial, prospective, randomized, blinded, and controlled for the treatment of osteoarthritis (degrees II and III and IV). The assay consists of two arms with 15 patients each one. Patients in the experimental arm will be given an intra-articular transplantation of allogenic MSC, expanded "Ex Vivo" with our GMP-compliant procedure (MSV, PEI No. 10-134, authorized by the Competent Authority; same as in NCT01183728). In the control arm a standard treatment with intra-articular injection of hyaluronic acid shall be given. We shall follow the evolution of pain, disability, quality of life and quantitative changes in structure and composition of cartilage determined by T2-weighted MRI relaxation (Cartigram) for one year.

Primary outcomes

  • Number of Participants With Adverse Events as a Measure of Safety and Tolerability

History

  1. Last registry update

  2. Results first posted

  3. Study completion

  4. Primary completion

  5. Registered

  6. Started